Expect a Limited Role for the New HIV Drug, Juluca

February 2018

Juluca (jah-LOO-kah, dolutegravir/rilpivirine) will be the first two-drug combo that's a COMPLETE treatment regimen for HIV.

Most patients use THREE meds to treat HIV...often two nucleoSIDE/ nucleoTIDE reverse transcriptase inhibitors (NRTIs) PLUS another antiretroviral from a different class.

Juluca doesn't have an NRTI. It combines the integrase inhibitor, dolutegravir (Tivicay), with the NON-nucleoside reverse transcriptase inhibitor, rilpivirine (Edurant). It's a single tablet taken once daily.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Diabetes Meds Look for New GLP-1 Agonist and Flozin Options for Type 2 Diabetes
Monitoring Compare Freestyle Libre and Other Continuous Glucose Monitors
Women's Health Ease Fears About Breast Cancer Risk With Hormonal Contraception
Supplements Be Aware That Biotin May Skew Lab Test Results
Cardiology Use "ABCDs" to Optimize Meds for Stable Coronary Artery Disease
Asthma Ensure Long-Acting Beta-Agonists Aren't Used Alone for Asthma
Travel Medicine Share Strategies to Limit Altitude Sickness
Psoriasis Know Key Points About Biologics for Psoriasis
HIV & AIDS Expect a Limited Role for the New HIV Drug, Juluca
Erectile Dysfunction Anticipate Interest in Generic Viagra (Sildenafil)
Practice Get Tools to Tackle This Flu Season

Expect a Limited Role for the New HIV Drug, Juluca

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents